NCT06800339 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06800339
Title	A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer (NEORADJUVANT)
Acronym	NEORADJUVANT
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	University of Maryland, Baltimore
Indications	lung non-small cell carcinoma
Therapies	Carboplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab
Age Groups:	senior \| adult
Covered Countries	USA

Additional content available in CKB BOOST